BioSpace News Archive

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided an update on its clinical programs targeting the small molecule correction of alpha-1 antitrypsin deficiency (AATD).

-- Is Oral Testosterone a Potential Treatment for COVID-19 in Men? -- TLANDO™, Oral Testosterone Replacement Therapy Without Dose Titration Requirement

NuVera Medical, Inc., a portfolio company of Shifamed LLC focused on enabling a new era in transcatheter cardiac interventions through the advancement of current 4D ICE imaging, today presented positive r

PierianDx, the leading clinical genomics informatics company, and Pillar Biosciences, a leading next-generation sequencing clinical oncology company, today announced a partnership that enables Pillar Biosciences to sell directly the PierianDx cli

Large Study Demonstrates Exceptional Safety and High Procedural Success With Cardiovascular Systems’ Diamondback 360 ® Coronary Orbital Atherectomy System (OAS) ST. PAUL, Minn.--( BUSINESS WIRE )-- Cardiovascular Systems, Inc. (CSI ® ) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that results from a large retrosp

TEPEZZA ® (teprotumumab-trbw) Data from the Phase 2 Clinical Trial Evaluate Longer-Term Responses in People Living with Thyroid Eye Disease (TED) -- New findings presented during the Academy of Managed Care Pharmacy Nexus 2020 Virtual Meeting showed most patients had at least some improvement in one or more disease parameters for up to one year following TEPEZZA treatment for TED, and are supported by recently announced long-term follow-up data from the Phas

Anika Chebrolu Takes Home Top Prize and Improving Lives Award at This Year’s 3M Young Scientist Challenge

Perrigo Company plc (NYSE; TASE: PRGO), a leading provider of Quality, Affordable Self-Care Products, today announced that it will release its third quarter financial results on Wednesday, November 4, 2020 . The Company will also host a conference call beginning at 8:00 a.m. (EST) .

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) disorders, today announced that the Company received written notification from the Listing Qualification Department of The NASDAQ Capital Market (“Nasdaq

RxRevu, the nation’s leading provider of prescription decision support solutions, has partnered with athenahealth, a leading supplier of network-enabled software and services for medical groups and health systems nationwide, to deploy SwiftRx® Direct™ – RxRevu’s Real-Time Prescription Benefit solution – within athenahealth’s electronic hea